| Clinical and Regulatory | |
|---|---|
| Event Type: | Phase 2 Results |
| Timing: | Q4 2016 |
| Designation(s): | Fast Track |
|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|
|
| Disease and Treatment | |
|---|---|
| Disease: | Oncology |
| Indication: | Metastatic Pancreatic Cancer |
| Lead Indication?: | Yes |
| Treatment Name: | PEGPH20 |
|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
|
|
| Company Information | |
|---|---|
| Co. Name: | Halozyme |
| Stock Symbol: | HALO |
| Shares Traded: | NASDAQ |
|
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
|
|
| Event Status | |
|---|---|
| Event Outcome: | Ongoing |
| Event Discussion: | Forums |
| Event Announcement(s): | http://www.halozyme.com/investors/news-releases/news-release-details/2016/Halozyme-Reports-Second-Quarter-2016-Financial-Results/default.aspx |
| Partnership: | Yes |
|
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
|
|
Detailed Event Description from Company Announcement
QuotePresenting key efficacy and safety data from stage 1 of its phase 2 clinical study in metastatic pancreatic cancer patients treated with PEGPH20 at the 2016 American Society of Clinical Oncology Annual Conference. The results continued to show clinically meaningful efficacy for HA-high patients treated with PEGPH20 plus gemcitabine and ABRAXANE® (nab-paclitaxel) versus gemcitabine and ABRAXANE alone, including median progression free survival of 9.2 months versus 6.0 months. Safety data presented from stage 2 of the study continued to show a reduction in the rate of thromboembolic events in both treatment arms as compared to stage 1.
The company expects to report mature response rate and progression free survival data from stage 2 of the study in the fourth quarter.